New clinical data highlight improved disease control, reduced eye bulging, and weight-loss benefits, potentially broadening options for patients with unmet needs.
|Articles|May 23, 2007
Career Opportunities in Regulatory Affairs
Author(s)BioPharm International Editors
Shire's Human Genetic Therapies team, based in Cambridge, MA, specializes in discovering, developing, and commercializing protein therapeutics primarily for the treatment of genetic diseases.
Advertisement
Shire's Human Genetic Therapies team, based in Cambridge, MA, specializes in discovering, developing, and commercializing protein therapeutics primarily for the treatment of genetic diseases. Opportunities are now available for the following:
- Senior Manager, CMC Regulatory Affairs
- Senior Director, CMC Regulatory Affairs
- Manager, International Regulatory Affairs
- Manager, International Regulatory Operations
- Senior Technical Writer
- Senior Technical Writing Consultant
- Regulatory Documentation Specialist II
For more info click
Advertisement
Related to this article
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Once-weekly amylin analog petrelintide produced up to 9.2% weight loss at 28 weeks in adults with obesity and type 2 diabetes, Zealand Pharma reports.
Teprotumumab N01 (Sycume) reduced eye bulging in 60.4% of patients with chronic, inactive thyroid eye disease in a phase 3 trial.
Tecentriq plus chemotherapy gains FDA approval for stage III dMMR colon cancer after a phase 3 trial showed improved disease-free survival.
New clinical milestones, manufacturing investments, and regulatory incentives could help developers overcome barriers to delivering treatments for patients with rare diseases.
Genglycos, the gene therapy that earned the voucher, will fund new Ultragenyx therapies for other rare and ultra-rare diseases.
Advertisement
Advertisement